Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Transgene SA (GB:0OCQ)
:0OCQ
Holding GB:0OCQ?
Track your performance easily
0OCQ Stock Chart & Stats
Day’s Range― - ―
52-Week Range€0.68 - €1.49
Previous CloseN/A
Volume384.00
Average Volume (3M)227.00
Market Cap
€97.65M
Enterprise ValueN/A
Total Cash (Recent Filing)$56.21M
Total Debt (Recent Filing)$52.33M
Price to Earnings (P/E)―
Beta0.50
Next Earnings
Mar 27, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.23
Shares Outstanding132,293,930
10 Day Avg. Volume130
30 Day Avg. Volume227
Standard Deviation0.12
R-Squared0.07
Alpha-0.00917
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)58.25
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
0OCQ FAQ
What was Transgene SA’s price range in the past 12 months?
Transgene SA lowest share price was €0.68 and its highest was €1.49 in the past 12 months.
What is Transgene SA’s market cap?
Transgene SA’s market cap is €97.65M.
When is Transgene SA’s upcoming earnings report date?
Transgene SA’s upcoming earnings report date is Mar 27, 2025 which is in 71 days.
How were Transgene SA’s earnings last quarter?
Currently, no data Available
Is Transgene SA overvalued?
According to Wall Street analysts Transgene SA’s price is currently Overvalued.
Does Transgene SA pay dividends?
Transgene SA does not currently pay dividends.
What is Transgene SA’s EPS estimate?
Transgene SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Transgene SA have?
Transgene SA has 132,293,930 shares outstanding.
What happened to Transgene SA’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Transgene SA?
Currently, no hedge funds are holding shares in GB:0OCQ
---
Company Description
Transgene SA
Transgene SA is a biotechnology company. It is involved in the business of discovering and focusing immune-targeted therapies for the treatment of cancer and infectious diseases. The company's lead clinical-stage programs are TG4010 for non-small cell lung cancer and Pexa-vec for liver cancer. Its product pipeline includes TG4001, TG1050, TG6002 etc. The firm is based in Strasbourg, France has additional operations in Lyon as well as satellite offices in China and United States.
---
Technical Analysis
---